Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258217 · ClinicalTrials.gov registry record · NA
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
A NA study of Relapsing Remitting Multiple Sclerosis, sponsored by OhioHealth.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02258217 is a NA study of Relapsing Remitting Multiple Sclerosis that has completed, run by OhioHealth. The registered enrollment target is 30 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02258217, a NA study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by OhioHealth.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
Conditions Studied
Interventions
- DRUG Acthar
Study Locations (1)
Ohio
- OhioHealth - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258217
The ClinicalTrials.gov registry entry for NCT02258217 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower). The listed sponsor is OhioHealth, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Acthar is the first listed.
NCT02258217 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02258217 about?
NCT02258217 is a clinical study titled "Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)". Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
What is the current status of trial NCT02258217?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2016-12.
What conditions does trial NCT02258217 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT02258217?
The interventions under investigation include: Acthar (DRUG).
Who is sponsoring clinical trial NCT02258217?
This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02258217 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Development of a Motivational Intervention to Improve Treatment Adherence in MS
COMPLETED · NA
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.